Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

Erstveröffentlichung
2017Autoren
Seymour, John F.
Döhner, Hartmut
Butrym, Aleksandra
Wierzbowska, Agnieszka
Selleslag, Dominik
Wissenschaftlicher Artikel
Erschienen in
BMC Cancer ; 17 (2017). - Art.-Nr. 852. - ISSN 1471-2407
Link zur Veröffentlichung
https://dx.doi.org/10.1186/s12885-017-3803-6Institutionen
UKU. Klinik für Innere Medizin IIISchlagwörter
[Freie Schlagwörter]: Azacitidine | Low-dose cytarabine | Acute myeloid leukaemia | AML | Myelodysplasia-related changes | AML-MRC | Induction chemotherapy | Response | Survival | independent prognostic relevance | world-health-organization | multilineage dysplasia | morphologic dysplasia | classification | reproducibility | cytogenetics | mutations | neoplasms[DDC Sachgruppe]: DDC 610 / Medicine & health